Latest The Spectranetics Corp (SPNC) Headlines
Post# of 33
Posted On: 03/13/2014 2:14:26 PM
Latest The Spectranetics Corp (SPNC) Headlines
Uptrend Call Working As Spectranetics Stock Rises 75.1% (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 11:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 75.08% as of today's recent price of $30.35.
Post Earnings Update: Spectranetics Has Climbed 7.0% Higher in Past Week (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
A week ago on February 27th, 2014 Spectranetics (NASDAQ:SPNC) reported earnings and analysts, on average, expected earnings of $0.02 on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Since the company's report, shares of Spectranetics have risen from $28.75 to $30.75, representing a gain of 7.0% in the past 11 days.
70.2% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 70.23% as of today's recent price of $29.51.
Spectranetics Achieves Fourth Quarter Revenue of $41.9 Million
GlobeNewswire - Thu Feb 27, 3:14PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the quarter and year ended December 31, 2013. Highlights of the quarter (all compared with the quarter ended December 31, 2012) include:
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Spectranetics Achieves Statistical Endpoints of EXCITE ISR Adjunct Analysis
GlobeNewswire - Mon Feb 24, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the EXCITE ISR trial achieved the statistical endpoints of the adjunct analysis. The trial evaluates laser atherectomy plus Percutaneous Transluminal Angioplasty (PTA) compared with PTA alone for the treatment of in-stent restenosis (ISR) in patients suffering from peripheral artery disease (PAD).
52.1% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Feb 24, 9:20AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.33. In approximately 5 months, Spectranetics has returned 52.12% as of today's recent price of $26.37.
Spectranetics to Hold 2013 Fourth Quarter Financial Results Conference Call on February 27
GlobeNewswire - Mon Feb 10, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2013 fourth quarter and year-end financial results after market close on Thursday, February 27, 2014. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 27 to discuss those results and to answer questions.
45.5% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Fri Feb 07, 11:11AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 4 months, Spectranetics has returned 45.54% as of today's recent price of $25.23.
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Mon Feb 03, 6:58AM CST
Spectranetics (NASDAQ:SPNC) was downgraded from Market Perform to Underperform at Northland today. The stock closed yesterday at $26.02 on volume of 391,000 shares, above average daily volume of 341,000. Spectranetics share prices have moved between a 52-week high of $26.29 and a 52-week low of $15.52 and closed yesterday at 68% above that low price at $26.02 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.6%.
Spectranetics Shares Up 45.7% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 24, 9:22AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 4 months, Spectranetics has returned 45.66% as of today's recent price of $25.25.
Companies Scheduled to Present at the Annual J.P. Morgan Healthcare Conference - Research Report on Mettler-Toledo, BioMarin, DexCom, Spectranetics, and Acorda
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Mettler-Toledo International Inc. (NYSE: MTD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), DexCom, Inc. (NASDAQ: DXCM), The Spectranetics Corporation (NASDAQ: SPNC), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Spectranetics Up 47.4% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Thu Jan 09, 11:14AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 3 months, Spectranetics has returned 47.39% as of today's recent price of $25.55.
Spectranetics to Present at the JP Morgan 32nd Annual Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the JP Morgan 32 Annual Healthcare Conference on January 15, 2014 in San Francisco.
MRI Interventions Adds Industry Veteran Maria Sainz as New Board Member
GlobeNewswire - Mon Jan 06, 7:00AM CST
MRI Interventions, Inc. (OTCQB:MRIC) today announced that its Board of Directors has elected veteran medical device executive Maria Sainz as its newest director. Ms. Sainz's distinguished career in the medical device industry spans over 20 years, and includes 10 years as the top executive for both emerging businesses and large corporate divisions, strong commercial experience bringing therapies to market, significant international experience, and service on both public and private company boards.
Uptrend Call Working As Spectranetics Stock Rises 75.1% (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 11:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 75.08% as of today's recent price of $30.35.
Post Earnings Update: Spectranetics Has Climbed 7.0% Higher in Past Week (SPNC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
A week ago on February 27th, 2014 Spectranetics (NASDAQ:SPNC) reported earnings and analysts, on average, expected earnings of $0.02 on sales of $41.0 million. The company actually reported EPS of $0.02 on sales of $41.9 million, matching EPS estimates and beating revenue estimates by $1.0 million. Since the company's report, shares of Spectranetics have risen from $28.75 to $30.75, representing a gain of 7.0% in the past 11 days.
70.2% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Mar 03, 9:37AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 5 months, Spectranetics has returned 70.23% as of today's recent price of $29.51.
Spectranetics Achieves Fourth Quarter Revenue of $41.9 Million
GlobeNewswire - Thu Feb 27, 3:14PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today reported financial results for the quarter and year ended December 31, 2013. Highlights of the quarter (all compared with the quarter ended December 31, 2012) include:
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Spectranetics Achieves Statistical Endpoints of EXCITE ISR Adjunct Analysis
GlobeNewswire - Mon Feb 24, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the EXCITE ISR trial achieved the statistical endpoints of the adjunct analysis. The trial evaluates laser atherectomy plus Percutaneous Transluminal Angioplasty (PTA) compared with PTA alone for the treatment of in-stent restenosis (ISR) in patients suffering from peripheral artery disease (PAD).
52.1% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Mon Feb 24, 9:20AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.33. In approximately 5 months, Spectranetics has returned 52.12% as of today's recent price of $26.37.
Spectranetics to Hold 2013 Fourth Quarter Financial Results Conference Call on February 27
GlobeNewswire - Mon Feb 10, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2013 fourth quarter and year-end financial results after market close on Thursday, February 27, 2014. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 27 to discuss those results and to answer questions.
45.5% Return Seen to Date on SmarTrend Spectranetics Call (SPNC)
Comtex SmarTrend(R) - Fri Feb 07, 11:11AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 4 months, Spectranetics has returned 45.54% as of today's recent price of $25.23.
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Mon Feb 03, 6:58AM CST
Spectranetics (NASDAQ:SPNC) was downgraded from Market Perform to Underperform at Northland today. The stock closed yesterday at $26.02 on volume of 391,000 shares, above average daily volume of 341,000. Spectranetics share prices have moved between a 52-week high of $26.29 and a 52-week low of $15.52 and closed yesterday at 68% above that low price at $26.02 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.6%.
Spectranetics Shares Up 45.7% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Fri Jan 24, 9:22AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 4 months, Spectranetics has returned 45.66% as of today's recent price of $25.25.
Companies Scheduled to Present at the Annual J.P. Morgan Healthcare Conference - Research Report on Mettler-Toledo, BioMarin, DexCom, Spectranetics, and Acorda
PR Newswire - Fri Jan 10, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Mettler-Toledo International Inc. (NYSE: MTD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), DexCom, Inc. (NASDAQ: DXCM), The Spectranetics Corporation (NASDAQ: SPNC), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Spectranetics Up 47.4% Since SmarTrend Uptrend Call (SPNC)
Comtex SmarTrend(R) - Thu Jan 09, 11:14AM CST
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on October 2nd, 2013 at $17.34. In approximately 3 months, Spectranetics has returned 47.39% as of today's recent price of $25.55.
Spectranetics to Present at the JP Morgan 32nd Annual Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the JP Morgan 32 Annual Healthcare Conference on January 15, 2014 in San Francisco.
MRI Interventions Adds Industry Veteran Maria Sainz as New Board Member
GlobeNewswire - Mon Jan 06, 7:00AM CST
MRI Interventions, Inc. (OTCQB:MRIC) today announced that its Board of Directors has elected veteran medical device executive Maria Sainz as its newest director. Ms. Sainz's distinguished career in the medical device industry spans over 20 years, and includes 10 years as the top executive for both emerging businesses and large corporate divisions, strong commercial experience bringing therapies to market, significant international experience, and service on both public and private company boards.
(0)
(0)